Schroder Investment Management Group decreased its stake in Core Laboratories N.V. (NYSE:CLB) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 217,231 shares of the oil and gas company’s stock after selling 3,895 shares during the period. Schroder Investment Management Group owned 0.49% of Core Laboratories worth $21,337,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CLB. Alliancebernstein L.P. lifted its holdings in shares of Core Laboratories by 18.6% in the 1st quarter. Alliancebernstein L.P. now owns 2,494 shares of the oil and gas company’s stock worth $288,000 after purchasing an additional 392 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Core Laboratories by 9.7% in the 2nd quarter. Aperio Group LLC now owns 5,882 shares of the oil and gas company’s stock worth $596,000 after purchasing an additional 518 shares during the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Core Laboratories by 2.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 11,676 shares of the oil and gas company’s stock worth $1,182,000 after purchasing an additional 309 shares during the last quarter. Korea Investment CORP lifted its holdings in shares of Core Laboratories by 22.9% in the 2nd quarter. Korea Investment CORP now owns 53,600 shares of the oil and gas company’s stock worth $5,428,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Callahan Advisors LLC lifted its holdings in shares of Core Laboratories by 2.5% in the 2nd quarter. Callahan Advisors LLC now owns 2,075 shares of the oil and gas company’s stock worth $210,000 after purchasing an additional 50 shares during the last quarter.

Core Laboratories N.V. (NYSE CLB) opened at $104.50 on Tuesday. Core Laboratories N.V. has a 1 year low of $86.55 and a 1 year high of $125.83. The stock has a market capitalization of $4,637.24, a price-to-earnings ratio of 57.40 and a beta of 1.56. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.81 and a current ratio of 2.18.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.04. Core Laboratories had a return on equity of 52.89% and a net margin of 12.06%. The company had revenue of $166.20 million for the quarter, compared to analysts’ expectations of $160.94 million. During the same period last year, the firm earned $0.38 EPS. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. sell-side analysts predict that Core Laboratories N.V. will post 1.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, November 21st. Stockholders of record on Friday, October 20th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.11%. The ex-dividend date of this dividend was Thursday, October 19th. Core Laboratories’s dividend payout ratio (DPR) is presently 126.44%.

Several analysts have weighed in on the company. Zacks Investment Research downgraded Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. UBS cut their target price on Core Laboratories from $110.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 25th. ABN Amro raised Core Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, October 25th. Loop Capital cut their target price on Core Laboratories from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Wednesday, October 25th. Finally, Scotiabank set a $136.00 target price on Core Laboratories and gave the company a “hold” rating in a research note on Wednesday, October 25th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $108.64.

WARNING: This piece was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://theolympiareport.com/2017/12/05/core-laboratories-n-v-clb-shares-sold-by-schroder-investment-management-group.html.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.